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Background: Microglia-mediated proteolysis of the triggering receptor expressed on myeloid 
cells (TREM-2) produces soluble TREM-2 (sTREM-2) that can be measured in cerebrospinal 
fluid (CSF) samples. Loss-of-function mutations in TREM2 or in the gene encoding its 
adaptor protein cause the rare Nasu-Hakola disease (NHD). Multiple sclerosis (MS) is an 
autoimmune disease that in common with NHD is characterized by demyelination and 
microglial activation.  
Objective: To investigate the potential utility of sTREM-2 as a biomarker for MS and to 
follow treatment effects. 
Methods: Soluble TREM-2 was analyzed in CSF samples from subjects with MS (N=59); 
relapsing-remitting MS (RRMS) (N=36), secondary progressive MS (SPMS) (N=20) and 
primary progressive MS (PPMS) (N=3), and controls (N=27). CSF levels of sTREM-2 were 
also assessed before and after treatment of patients with natalizumab or mitoxantrone. 
Results: CSF levels of sTREM-2 were significantly increased in patients with RRMS, SPMS 
and PPMS compared with controls. After natalizumab treatment, the levels of sTREM-2 were 
normalized to control levels. The levels of sTREM-2 were also reduced after mitoxantrone 
treatment. 
Conclusion: Increased CSF levels of sTREM-2, a new marker of microglial activation, in MS 
and normalization upon treatment with either natalizumab or mitoxantrone support a role for 





Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central 
nervous system (CNS).1 The disease process involves CNS injury by auto-reactive immune 
cells, which leads to demyelination and damage of axons. Even though MS is primarily an 
inflammatory disease of the CNS, the pathological changes over time become dominated by 
microglial activation associated with extensive and chronic neurodegeneration.1 The disease 
usually begins with a relapsing-remitting course (RRMS) that may shift into a secondary 
progressive phase (SPMS) that carries features of neurodegenerative diseases. A few patients 
have a progressive onset with slowly increasing neurological dysfunction, which is termed 
primary progressive multiple sclerosis (PPMS).1 
 
Triggering receptors expressed on myeloid cells (TREM-2) is a cell surface receptor 
predominantly expressed on myeloid cells, e.g. monocyte-derived dendritic cells, 
macrophages, mast cells, osteoclasts and microglia.2, 3 Previous studies have identified 
microglia as the brain cells expressing the highest levels of TREM-2.4 Activation of the 
TREM-2 receptor in most myeloid cells investigated so far attenuates the immune response.5 
Knowledge on the normal physiological functions of TREM-2 is inadequate and loss-of-
function mutations in humans have contributed to most information regarding its potential 
role. Nasu-Hakola disease (NHD; polycystic lipomembranous osteodysplasia with sclerosing 
leukoencephalopathy), is caused by missense mutations in TREM2 or the gene encoding its 
cytosolic DNAX adaptor protein 12 (DAP12).6 This rare disorder is characterized by 
demyelination of the CNS, presenile dementia and bone cysts.6 Recently, genome-wide 
association studies have also shown that rare variants in the TREM2 gene are associated with 
an increased risk of Alzheimer’s disease.7, 8 Recent reports have also demonstrated an 
 
 
association of TREM2 variants with Parkinson’s disease, amyotrophic lateral sclerosis and 
frontotemporal dementia9-11, while TREM2 has not yet been genetically linked to MS. The 
TREM-2 receptor undergoes ectodomain shedding producing soluble TREM-2 (sTREM-2)12 
that possibly corresponds to the form of TREM-2 that has previously been observed in CSF 
samples from patients with MS, frontotemporal dementia and Alzheimer’s disease.13, 14 
 
In the present study, we analyzed sTREM-2 in CSF samples from subjects in various stages of 
MS (RRMS, SPMS and PPMS) and healthy controls. The CSF levels of sTREM-2 were also 






Materials and Methods 
Patients and healthy controls 
The study included 58 MS patients15, 16; 36 RRMS, 20 SPMS, and three PPMS17 and 27 
healthy controls. The study was approved by the regional ethical board of the University of 
Gothenburg, Sweden. Informed consent was obtained from all participants. Patients were 
recruited from two patient cohorts at the Department of Neurology, Sahlgrenska University 
Hospital, Gothenburg, Sweden. Both patient groups have been described previously.18, 19 
Group 1 consisted of patients who were scheduled to start treatment with 300 mg natalizumab 
intravenously once monthly according to Swedish guidelines (www.mssallskapet.se). All 
patients in this group (37 RR-, 1 SP- and 1 PPMS) presented either a highly active disease 
course de novo or breakthrough disease activity in terms of relapses in the presence of first 
line disease-modifying treatments (DMTs). Group 2 consisted of patients (1 RR-, 19 SP- and 
1 PPMS) about to start treatment with mitoxantrone (intravenous administration 12 mg/m2 at 
three-month intervals for 2 years; i.e., 8 infusions, total dose 96 mg/m2) according to 
established regimens20 and Swedish guidelines (www.mssallskapet.se).  
Healthy controls were blood donors or students with no history of neurological disease and no 
abnormal signs were found at neurological examination. All participants underwent clinical 
neurological examination, peripheral blood sampling, and lumbar puncture. Disease duration 
was estimated from onset of first demyelinating symptoms.  
Pooled decoded CSF samples supplied by the Clinical Neurochemistry Laboratory, Sahlgrenska 
University Hospital, from patients who underwent lumbar puncture to exclude infectious 




Clinical assessment and specimen sampling 
The neurological examinations were performed by trained neurologists, and disability was 
scored using the Expanded Disability Status Scale (EDSS).21 Disease progression and severity 
were measured using the Multiple Sclerosis Severity Score (MSSS).22 A relapse was defined 
according to McDonald criteria as an episode of neurological disturbance lasting for at least 
24 h.15 At baseline, 14 % of RRMS, 10% of SPMS and none of the PPMS had disease activity 
for up to 3 month prior to CSF sample were taken. In patients with RRMS patients, 15% had 
disease activity for up to 3 month prior to baseline, which was reduced to 4% after 9 month 
with natalizumab treatment. In patients with progressive MS, 11% of patients had disease 
activity for up to 3 month prior to baseline CSF and after 21 month treatment with 
mitoxantrone none of the patients had a relapse. 
 
CSF collection 
All CSF samples were obtained by lumbar puncture according to the procedures 
recommended in the consensus protocol of the BioMS-EU network for CSF biomarker 
research in MS.23 The CSF samples were centrifuged at 2,000 g for 10 min at room 
temperature to remove cells and debris, and stored in aliquots at –80 °C pending biochemical 
analysis.  
 
Analysis of sTREM-2 in CSF  
The CSF analyses on sTREM-2 were performed using a commercially available enzyme-
linked immunosorbent assay (ELISA) from Uscn Life Science Inc. (Cloud-Clone Corp., 
Houston, TX, USA) according to instructions by the manufacturer. Neat CSF samples were 
 
 
analyzed on the same day using assays from the same lot to avoid inter-lot variations. CSF 
samples from the control group were evenly distributed on the plates. Samples before and 
after treatment of each patient with natalizumab or mitoxantrone, were analyzed on the same 
plate. In this study, only patients treated with natalizumab or mitoxantrone who had CSF 
samples available at baseline and follow-up were included (Table 1). The intra-day coefficient 




Because the distribution of sTREM-2 was not normal (Shapiro-Wilk test, P < 0.05), non-
parametric statistics were used. Data are given as median (inter-quartile range) and percent 
differences, i.e. 100 x [(the median for a diagnostic group-the median for a second diagnostic 
group)/ the median for the second group]. Differences between more than two groups were 
assessed with Kruskal-Wallis test. For analysis of baseline data, statistically significant results 
(P<0.05) were followed by Mann-Whitney U-tests to investigate group differences. To adjust 
for potential confounding effects of age and gender, we performed analysis of covariance, 
analyzing log-transformed sTREM-2 values. Wilcoxon signed rank sum test were used for 
analysis of matched pair data, i.e. pre- and post-drug treatment. Receiver operating 
characteristic (ROC) curves were performed in order to assess the diagnostic value. Correlation 
coefficients (rho) were calculated using the Spearman two-tailed correlation test. SPSS 20.0 






The demographic data for the study populations are shown in Table 1. The study groups differed 
in gender and age distribution, with a larger proportion of females in the RRMS group, 
compared to controls and SPMS; and older subjects in the SPMS groups, as compared to the 
other groups. Subsequently gender and age were considered as potential confounding factors, 
adjusted for by analysis of covariance as described below. 
 
Soluble TREM-2 at baseline 
CSF levels of sTREM-2 were significantly higher in patients with RRMS (+140%, P<0.0001), 
SPMS (+183%, P<0.0001) and PPMS patients (+187%, P=0.02) compared with healthy 
controls (Figure 1). However, there were no significant differences in the levels of sTREM-2 
comparing each group of RRMS, SPMS and PPMS with each another.  
 
To adjust for potential confounding effects of gender and age distribution, we performed 
analysis of covariance, analyzing log transformed levels of sTREM-2 including age and gender 
as cofactors in the model. CSF levels of sTREM-2 were significantly higher in patients with 
RRMS (+140%, P<0.005), SPMS (+183%, P<0.0001) and PPMS (+187%, P=0.01) compared 
with healthy controls. There were no significant differences in the levels of sTREM-2 in RRMS 
versus SPMS or RRMS versus PPMS, while sTREM-2 was modestly altered in SPMS versus 
PPMS (+1.5%, P=0.02).  
 
Soluble TREM-2 in CSF could differentiate patients with RRMS (N=36), SPMS (N=20) and 
PPMS (N=3) from healthy controls (N=27), with AUC of 0.819 (95% CI 0.715-0.924, 
 
 
P<0.0001), 0.869 (95% CI 0.766-0.971, P<0.0001) and 0.914 (95% CI 0.779-1.049, P=0.02), 
respectively (Figure 2).  
 
There was a significant correlation between age and sTREM-2 in the SPMS group (rho=-
0.535, P=0.02), but not in either the control group (N=27) or the RRMS group (N=20) (data 
not shown). 
 
Soluble TREM-2 in relation to treatment 
The levels of sTREM-2 were significantly higher in MS patients before treatment with 
natalizumab (+155%, P<0.0001) compared with CSF levels in healthy controls, but were 
normalized at follow-up after 12 months of natalizumab treatment. The levels of sTREM-2 
were significantly higher both before and after mitoxantrone treatment (+306%, P<0.0001 and 
+148%, P=0.0007) compared with CSF sTREM-2 levels in healthy controls (Figure 3A). The 
comparison between pre- and post-natalizumab or mitoxantrone treatment showed that the 
levels of sTREM-2 were significantly decreased in the CSF (-51%, P=0.001 and -39%, P=0.04) 
(Figure 3B).  
 
Both the EDSS and MSSS scores were decreased after natalizumab treatment, showing clinical 
improvement following drug treatment (Figure 3C-D). There was no change in the clinical 
outcome determined by EDSS and MSSS due to mitoxantrone treatment (Figure 3C-D).  
 
Soluble TREM-2 in relation to disease duration and disease severity 
There were significant correlations between CSF sTREM-2 levels and disease duration in the 
total MS group (rho=-0.383, P=0.003) and RRMS group (rho=-0.366, P=0.033), but not in the 
 
 
SPMS group (Table 2). There were no significant correlations between sTREM-2 and clinical 
disease severity (EDSS or MSSS) in either the total MS group or the RRMS group. However, 




In the present study we found that the CSF levels of sTREM-2 were increased in all investigated 
forms of MS compared with healthy controls. After natalizumab treatment in patients with 
RRMS, sTREM-2 was reduced to a similar level as the healthy controls. Besides the altered 
sTREM-2 level, these patients had a clinical improvement as determined by EDSS and MSSS. 
After mitoxantrone treatment, the CSF levels of sTREM-2 were decreased in SPMS patients 
compared with before treatment. However, after mitoxantrone treatment the sTREM-2 levels 
were still higher compared to the controls and the clinical outcome remained unaltered.  
 
Activated microglia produce cytokines and have been described to remove myelin and tissue 
debris during the pathogenesis of MS.24 Myelin debris clearance has been shown to be 
essential for remyelination and repair of the damaged axons.25 Within the CNS, the TREM-2 
receptors appear to be exclusively expressed by microglial cells.4 In addition to TREM-2 
there are several other microglial receptors that are important for myelin debris 
phagocytosis.26 In the current study we found that the CSF levels of sTREM-2 were 
significantly higher in all examined stages of MS (RRMS, SPMS and PPMS) compared with 
healthy controls. This result is in concordance with the only previous study that showed 
increased levels of sTREM-2 in patients with RRMS and PPMS compared with subjects with 
non-inflammatory neurologic diseases.13 Soluble TREM-2 is produced by ectodomain 
 
 
shedding of its receptor, which simultaneously produces peptides that reduce the activity of 
the full-length receptor.12 So far most reports suggest that TREM-2 receptors modulate the 
innate immune response by reduction of the primarily induced immune signals, thus acting to 
inhibit inflammation.5 Several experimental models of MS have shown that blockade of the 
TREM-2 receptor exacerbates disease27-29. Moreover, disruption of the TREM-2/DAP12 
pathway in patients with NHD leads also to neurodegeneration and axonal loss6 and similarly 
to MS demyelination of the CNS. The elevated CSF levels of sTREM-2 found in patients with 
MS might indirectly reflect that the expression or activity of the TREM-2 receptor is reduced 
in response to chronic inflammation. Furthermore, microglial activation known to occur in 
MS correspond well to increased CSF levels of sTREM-2 compared to controls.  
 
Natalizumab is a monoclonal antibody targeting the α4 integrins and thereby reduces 
transmigration of lymphocytes from the periphery to the CNS.30 In RRMS it reduces disease 
activity and brain atrophy development.31 We have previously shown that natalizumab 
reduced CSF neurofilament light (NFL) levels (biomarker of axonal damage) to levels found 
in healthy controls and reduced the clinical severity.19 In the current study we found that 
natalizumab treatment decreased the levels of sTREM-2 in a similar way and was 
accompanied by improved clinical outcome. The anti-inflammatory effects due to 
natalizumab treatment have previously been shown by a reduction of pro-inflammatory 
cytokines and chemokines in CSF.32 Even though, natalizumab preliminary reduce the 
inflammation, there is supporting evidence that the microglial activation also is reduced after 
natalizumab treatment33 and that the cortical microglial activity correlate to disease severity in 
patients with MS.34 The TREM-2 receptor was recently shown to regulate the microglial cell 
activation in a demyelination mouse model.29 In this experimental model of MS, Cantoni et 
al. showed that TREM-2-deficient mice had defective clearance of myelin debris and more 
 
 
axonal pathology, which also resulted in impaired clinical performances.29 Interestingly, after 
natalizumab treatment there was a clinical improvement and simultaneously the levels of 
sTREM were decreased to control levels. Thus, sTREM-2 might be a valuable marker for 
studying treatment effects.  
 
Mitoxantrone is an immunosuppressive drug that reduces B- and T-lymphocytes and has 
shown beneficial effects in MS, including those with a progressive course of the disease.35 In 
the present study, we found that the CSF levels of sTREM-2 were reduced in progressive MS 
after mitoxantrone treatment, but still remained at higher levels than those recorded in healthy 
control subjects. We have previously shown that mitoxantrone reduced CSF NFL levels 
approaching those levels found in healthy controls.18 In contrast to the natalizumab-treated 
patients, there were no changes in the clinical outcome determined by EDSS and MSSS 
scores due to mitoxantrone treatment, which is consistent with our previous studies.18, 19 
 
 
A limitation of the present study was the absence of a placebo group that received no drug. 
Further, the intra-day coefficients of variance for QC samples analyzed at the same occasion 
were relatively high. Whereas this does not change any of the group differences observed, the 
assay may not be optimal to evaluate treatment effects on a case-by-case basis.  
 
In conclusion, we show that sTREM-2 in CSF could differentiate patients with RRMS, SPMS 
and PPMS from healthy controls. The levels of sTREM-2 were higher in CSF samples from 
MS patients compared to controls supporting evidence that sTREM-2 could be a marker of 
 
 
microglial activation in MS. CSF sTREM-2 also proved to be a dynamic marker that 
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Table 1 Demographic data for the study groupsa. 
 
Abbreviations: Expanded Disability Status Scale (EDSS), Multiple Sclerosis Severity Score 
(MSSS), primary progressing multiple sclerosis (PPMS), relapsing-remitting multiple 
sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS). 
aData are given as median (inter-quartile range) unless otherwise indicated. Statistical 
differences were determined using Mann-Whitney U-tests for the study population at baseline 
*P≤0.05 (compared with Controls), #P≤0.05, ##P≤0.01 and ###P≤0.001 (compared with RRMS) 
and Wilcoxon signed rank sum tests for natalizumab and mitoxantrone-treated patients at 



















Controls 27 (20/7) 40 (35-52)
# N.A. N.A. N.A. N.A. N.A. N.A.
RRMS 36 (11/25) 36 (29-44)* 6.5 (4-12) 3.5 (2.0-4.8) 3.0 (1.8-4.0) 4.2 (2.3-7.0) 3.7 (1.3-6.1) 12 (12-12)
SPMS 20 (10/10) 48 (41-56)*
































9 (6/3) 37 (34-50) 4 (3-8) 6 (6-6.5) 6.5 (6-6.5) 8.8 (8.7-9.6) 8.4 (8.2-9.1) 24 (23-24)
Study populations at baseline




Figure 1. Soluble TREM-2 levels in cerebrospinal fluid samples from healthy controls 
(N=27) and patients with relapsing-remitting multiple sclerosis (RRMS) (N=36), secondary 
progressive multiple sclerosis (SPMS) (N=20) and primary progressing multiple sclerosis 
(PPMS) (N=3). The lower, upper and middle lines of the error bars correspond to the 25th and 
75th percentiles and medians, respectively. 
 
Figure 2. Receiver operating characteristic (ROC) curve analysis of sTREM-2 in cerebrospinal 
fluid for differentiation of relapsing-remitting multiple sclerosis (RRMS) (N=36) (black), 
secondary progressive multiple sclerosis (SPMS) (N=20) (purple) and primary progressing 
multiple sclerosis (PPMS) (N=3). The area under the curve was 0.819 (95% CI 0.715-0.924, 
P<0.0001), 0.869 (95% CI 0.766-0.971, P<0.0001) and 0.914 (95% CI 0.779-1.049, P=0.02), 
respectively. 
 
Figure 3. Individual CSF values of sTREM-2 (A) in MS patients pre- and post-treatment with 
natalizumab (Nz) (N=27) and mitoxantrone (Mtx) (N=9), respectively, and in healthy controls 
(N=27). Individual CSF values of sTREM-2 (B), Expanded Disability Status Scale (EDSS) 
(C) and Multiple Sclerosis Severity Score (MSSS) (D) pre- and post-treatment with Nz and 
Mtx. The lower, upper and middle lines of the error bars correspond to the 25th and 75th 
percentiles and medians, respectively. Differences between more than two groups were 
assessed with Kruskal-Wallis test. Mann-Whitney U-test was used to investigate group 
differences (A) and Wilcoxon signed rank sum test were used for analysis of paired data (B-
D). The lower, upper and middle lines of the error bars correspond to the 25th and 75th 
percentiles and medians, respectively. 
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